KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Jan 23, 2026 >>  ABB India 4691.75  [ -1.39% ]  ACC 1670.35  [ -3.32% ]  Ambuja Cements 518.85  [ -5.01% ]  Asian Paints Ltd. 2702.25  [ -0.03% ]  Axis Bank Ltd. 1260.1  [ -2.72% ]  Bajaj Auto 9413.3  [ 0.51% ]  Bank of Baroda 296.2  [ -2.95% ]  Bharti Airtel 1985.25  [ -0.84% ]  Bharat Heavy Ele 242.5  [ -3.60% ]  Bharat Petroleum 349.3  [ -1.37% ]  Britannia Ind. 5834.1  [ -1.66% ]  Cipla 1314.85  [ -4.13% ]  Coal India 418.55  [ -1.08% ]  Colgate Palm 2164.95  [ -0.67% ]  Dabur India 518.65  [ -1.25% ]  DLF Ltd. 588.6  [ -4.08% ]  Dr. Reddy's Labs 1235.15  [ 1.48% ]  GAIL (India) 161.15  [ -1.47% ]  Grasim Inds. 2760.4  [ -1.00% ]  HCL Technologies 1706.6  [ 0.23% ]  HDFC Bank 916.25  [ -0.34% ]  Hero MotoCorp 5391.55  [ -1.75% ]  Hindustan Unilever 2412.05  [ 0.92% ]  Hindalco Indus. 950.3  [ 0.60% ]  ICICI Bank 1343.35  [ -0.17% ]  Indian Hotels Co 644.9  [ -1.78% ]  IndusInd Bank 893.1  [ -1.04% ]  Infosys L 1670.6  [ 0.44% ]  ITC Ltd. 323.45  [ -0.45% ]  Jindal Steel 1063.05  [ -1.24% ]  Kotak Mahindra Bank 422.2  [ -0.85% ]  L&T 3745.05  [ -1.30% ]  Lupin Ltd. 2137.15  [ -1.29% ]  Mahi. & Mahi 3542.6  [ -0.84% ]  Maruti Suzuki India 15469.6  [ -1.87% ]  MTNL 29.02  [ -4.26% ]  Nestle India 1293.3  [ -0.96% ]  NIIT Ltd. 73.99  [ -3.47% ]  NMDC Ltd. 76.4  [ -2.39% ]  NTPC 336.8  [ -1.66% ]  ONGC 245.55  [ 0.64% ]  Punj. NationlBak 120.15  [ -4.00% ]  Power Grid Corpo 254.2  [ -2.06% ]  Reliance Inds. 1385.95  [ -1.13% ]  SBI 1029.4  [ -1.80% ]  Vedanta 684.4  [ 0.87% ]  Shipping Corpn. 201.8  [ -2.70% ]  Sun Pharma. 1631.65  [ -0.17% ]  Tata Chemicals 714.1  [ -2.12% ]  Tata Consumer Produc 1153.25  [ -1.87% ]  Tata Motors Passenge 344.2  [ -0.89% ]  Tata Steel 187.55  [ -0.92% ]  Tata Power Co. 345.3  [ -1.95% ]  Tata Consultancy 3160.85  [ 0.30% ]  Tech Mahindra 1701.35  [ 0.79% ]  UltraTech Cement 12368.3  [ 0.03% ]  United Spirits 1333  [ -0.44% ]  Wipro 238.35  [ -0.98% ]  Zee Entertainment En 81.39  [ -4.36% ]  
  • Share Prices
  • Tools
  • News
  • Company Details
  • Financial Data
  • Results
  • Key Financial Ratios
  • Reports
  • Corporate Announcements
  • Equity History

    • Company Information

    Indian Indices
    • Loading....

    Global Indices
    • Loading....

    Forex
    • Loading....

    MANKIND PHARMA LTD.

    23 January 2026 | 12:00

    Industry >> Pharmaceuticals

    Select Another Company

    ISIN No INE634S01028 BSE Code / NSE Code 543904 / MANKIND Book Value (Rs.) 370.30 Face Value 1.00
    Bookclosure 08/08/2025 52Week High 2717 EPS 48.23 P/E 43.70
    Market Cap. 87002.80 Cr. 52Week Low 2082 P/BV / Div Yield (%) 5.69 / 0.00 Market Lot 1.00
    Security Type Other

    History of Company

    The company history sections lists out major chronological events that happened to the company.
    The Company was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name "Mankind Pharma Private Limited", pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi ("RoC"). Pursuant to the conversion of the Company to a public limited company and as approved by the Shareholders pursuant to a special resolution dated July 14, 2005 the name of the Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh certificate of incorporation on April 13, 2006.

    Major events and milestones:

    2004 
    -Entered the chronic pharmaceutical segment with the launch of `Amlokind' tablets and `Glimestar' tablets amongst others

    2005 
    -Set up the first manufacturing facility at Paonta Sahib, Himachal Pradesh
    -Entered the ophthalmic pharmaceutical segment with the launch of `Lubistar Eye Drops' and `Tobastar Eye Drops' amongst others

    2007 
    -Entered the consumer healthcare segment with the launch of `Manforce' brand
    -Entered the animal healthcare segment with launch of `Bandykind' and `Ceftiforce' amongst othersRaised Rs.720 million from Monet Limited

    2009 
    -Set up the manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh

    2010 
    -Launched `Preganews' brand in the consumer healthcare segment

    2012 
    -Setup the first R&D centre at IMT Manesar, Haryana

    2014 
    -Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan)
    -Set up the manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh

    2015 
    -Incorporated the Subsidiary, Lifestar Pharma LLC in the US
    -Incorporated the Subsidiary, Mankind Pharma Pte. Limited in Singapore

    2017 
    -Set up the manufacturing facility in Sikkim

    2018 
    -The manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time

    2019 
    -Entered the female infertility segment with the launch of `Dydroboon' tablets

    2020 
    -Incorporated the Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal
    -Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of `Cilaheart' tablets and `Statpure' tablets
    -Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of `Zukanorm' tablets

    2021 
    -Incorporated the Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE
    -Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of `Mlife' tablets
    -Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of `Trugaba-NT' tablets and `Prebris-MNT' tablets

    2022 
    -Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited
    -Entered into transplant segment with the launch of `Pangraf Capsules' and `Mycept' tablets amongst others
    -Entered into oncology segment with the launch of `Pacliall' injection amongst others
    -Acquired the brands `Daffy' and `Combihale' from Dr. Reddy's Laboratories
    -The Subsidiary, Mankind Life Sciences Private Limited acquired 90.00% of the issued, subscribed and paid-up share capital of Upakarma Ayurveda Private Limited.

    2023
    -Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing Commitment to Excellence.
    -Mankind Pharma announced its partnership with SpiceJet to raise awareness about DMF-grade API.
    -Mankind Pharma Product Prega News and Sonam Kapoor partners to transform from pregnancy detection card to pregnancy care solution.

    2024
    -Mankind Pharma Completes Landmark Acquisition of BSV.
    -Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab.
    -Mankind Pharma Launches 45-Day Healthcare Mission at Mahakumbh Serving Thousands of Pilgrims with Free Health Check-ups.
    -Mankind Pharma Prodct Healthok has joined hands with Bikanervala, (Multinational Indian Restaurant and Sweets Chain).

    2025
    -The Scheme of Arrangement for Amalgamation amongst Shree Jee Laboratory Private Limited , JPR Labs Private Limited  and Jaspack Industries Private Limited  with Mankind Pharma Limited

    Way2Wealth Brokers Private Limited - CIN U67120KA2000PTC027628 Stock Broking: SEBI Regn No.: INZ000178638 | Exchange Membership ID: NSE: 11502, BSE: 3117, MSEI:51000, MCX: 56730 Depository Participant: SEBI Regn No. IN-DP-472-2020 | CDSL ID: 12062900 & 12031500, NSDL ID: IN303077 | Research Analyst: SEBI Regn No. INH200008705 | PMS: SEBI Regn No.INP000000829 | Register with AMFI ARN: 77558 (Date of Initial registration - 8th Dec 2009, Date of expiry - 24th Jan 2027) | PFRDA: POP226012019

    Way2Wealth Commodities Private Limited - CIN U51229KA2006PTC039880 Stock Broking: SEBI Regn No.: INZ000049130 | Exchange Membership ID: NCDEX : 00908

    Copyrights @ 2014 © Way2Wealth Brokers Pvt. Ltd. All rights reserved

    Designed, developed and content provided by  Dion

    Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.